Skip to content
10-K

Annual Report

ImmunoCellular Therapeutics, Ltd.

0000822411-18-000004

← back to feed
Filed
Mar 14, 2018 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2017 · Mar 1, 2018 41.93M sh
Capex FY 2017 · Dec 31, 2017 $0
Capex FY 2017 · Dec 31, 2016 $4.02K
Capex FY 2017 · Dec 31, 2015 $169.75K
Operating Cash Flow FY 2017 · Dec 31, 2017 −$16.67M
Operating Cash Flow FY 2017 · Dec 31, 2016 −$19.86M
Operating Cash Flow FY 2017 · Dec 31, 2015 −$19.04M
Long Term Debt FY 2017 · Dec 31, 2017 $0
Long Term Debt FY 2017 · Dec 31, 2016 $6.95M
Cash And Equivalents FY 2017 · Dec 31, 2017 $6.63M
Cash And Equivalents FY 2017 · Dec 31, 2016 $11.44M
Cash And Equivalents FY 2017 · Dec 31, 2015 $22.6M
Cash And Equivalents FY 2017 · Dec 31, 2014 $23.22M
Stockholders Equity FY 2017 · Dec 31, 2017 $4.65M
Stockholders Equity FY 2017 · Dec 31, 2016 $6.13M
Stockholders Equity FY 2017 · Dec 31, 2015 $21.72M
Stockholders Equity FY 2017 · Dec 31, 2014 $23.29M
Current Liabilities FY 2017 · Dec 31, 2017 $2.36M
Current Liabilities FY 2017 · Dec 31, 2016 $3.24M
Total Liabilities FY 2017 · Dec 31, 2017 $2.36M
Total Liabilities FY 2017 · Dec 31, 2016 $10.76M
Current Assets FY 2017 · Dec 31, 2017 $7.01M
Current Assets FY 2017 · Dec 31, 2016 $13.41M
Total Assets FY 2017 · Dec 31, 2017 $7.01M
Total Assets FY 2017 · Dec 31, 2016 $16.89M
Sga Expense FY 2017 · Dec 31, 2017 $4.03M
Sga Expense FY 2017 · Dec 31, 2016 $5.01M
Sga Expense FY 2017 · Dec 31, 2015 $4.62M
Rd Expense FY 2017 · Dec 31, 2017 $17.13M
Rd Expense FY 2017 · Dec 31, 2016 $19.11M
Rd Expense FY 2017 · Dec 31, 2015 $10.9M
Net Income FY 2017 · Dec 31, 2017 −$14.31M
Net Income FY 2017 · Dec 31, 2016 −$22.09M
Net Income FY 2017 · Dec 31, 2015 −$12.79M
Operating Income FY 2017 · Dec 31, 2017 −$21.15M
Operating Income FY 2017 · Dec 31, 2016 −$24.11M
Operating Income FY 2017 · Dec 31, 2015 −$15.51M
Revenue FY 2017 · Dec 31, 2017 $0
Revenue FY 2017 · Dec 31, 2016 $0
Revenue FY 2017 · Dec 31, 2015 $0